Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague
Crucell N.V. announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac®-based vaccines against anthrax and plague and test them in non-human primates.
Like Ebola and Marburg, anthrax and plague are among the so-called 'Category A' agents, which are considered by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to pose a significant risk in the event of use as bioterrorist agents. Category A agents can be easily disseminated or transmitted from person-to-person, result in high rates of mortality, may cause public panic and require special action for public health preparedness.
Crucell is already in the course of developing an Ebola vaccine with the Vaccine Research Center (VRC) of the US National Institutes of Health and the US Army Medical Research Institute for Infectious Diseases (USAMRIID), utilizing adenovirus vector technology and PER.C6® production technology. The same technology will be used for the collaboration with the US Navy on anthrax and plague. Under the terms of the CRADA, Crucell has obtained an option on exclusive commercialization rights to any vaccine that could result from the collaboration.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Protein team produces molecular barrels - Researchers show that two protein machineries collaborate on the development of barrel structures in the mitochondria
Deinove signs a collaboration agreement with the Tereos group
ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds - Company to Develop TAP Compound to Novel Target Using Centocor Antibody
Akzo Nobel's new business Nobilon has started operating - Nobilon will develop, produce and market human vaccines -- Diosynth, Intervet and Oregon are expected to give support

Fantastic muscle proteins and where to find them - “This is going to be unexpected even for myosin researchers”
Rigontec GmbH Appoints Dr. Christian Schetter as CEO
Light in sight - Restoring vision to blind mice
Category:Medicinal_chemistry
